NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Sell
34
HCAT Quote, Financials, Valuation and Earnings
Last price:
$6.98
Seasonality move
:
-12.17%
Day range:
$6.75 - $7.25
52-week range:
$5.42 - $11.41
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.39x
P/B ratio:
1.22x
Volume:
936.5K
Avg. volume:
571.5K
1-year change:
-21.2%
Market cap:
$432M
Revenue:
$295.9M
EPS (TTM):
-$1.35
Analysts' Opinion
-
Consensus RatingHealth Catalyst has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Health Catalyst has an estimated upside of 60.69% from its current price of $7.10.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $7.10.
Fair Value
-
According to the consensus of 0 analysts, Health Catalyst has 60.69% upside to fair value with a price target of -- per share.
HCAT vs. S&P 500
-
Over the past 5 trading days, Health Catalyst has underperformed the S&P 500 by -9.34% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Health Catalyst does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Health Catalyst has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Health Catalyst reported revenues of $76.4M.
Earnings Growth
-
Health Catalyst has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Health Catalyst reported earnings per share of -$0.24.
Enterprise value:
389.8M
EV / Invested capital:
0.56x
Price / LTM sales:
1.39x
EV / EBIT:
--
EV / Revenue:
1.29x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-25.09x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$136.6M
Return On Assets:
-10.95%
Net Income Margin (TTM):
-26.2%
Return On Equity:
-21.76%
Return On Invested Capital:
-12.86%
Operating Margin:
-17.93%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $271.8M | $290M | $302.1M | $73.8M | $76.4M | |
| Gross Profit | $133M | $132.4M | $136.6M | $32M | $34M | |
| Operating Income | -$148M | -$130.9M | -$85.1M | -$24.6M | -$13.7M | |
| EBITDA | -$98.4M | -$72.5M | -$26.2M | -$10M | $908K | |
| Diluted EPS | -$2.94 | -$2.23 | -$1.35 | -$0.39 | -$0.24 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $322.8M | $515.3M | $443.5M | $408.5M | $457.4M | |
| Total Assets | $570.7M | $845.5M | $776.2M | $712.9M | $813.1M | |
| Current Liabilities | $65.9M | $263.4M | $91.1M | $84.3M | $323.8M | |
| Total Liabilities | $271M | $296.3M | $336.2M | $330.5M | $458M | |
| Total Equity | $299.6M | $549.2M | $440M | $382.4M | $355M | |
| Total Debt | $166.2M | $177.8M | $226.1M | $227.7M | $345M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$30.2M | -$28.9M | -$955K | $3.1M | $6.2M | |
| Cash From Investing | -$122M | -$3.4M | $119.8M | -$24.9M | $7.6M | |
| Cash From Financing | $666K | $3M | $114.5M | $1M | $112.5M | |
| Free Cash Flow | -$47M | -$44.5M | -$15.5M | $6K | $1.8M | |
HCAT
Sector
Market Cap
$432M
$43.9M
Price % of 52-Week High
62.23%
45.73%
Dividend Yield
0%
0%
Shareholder Yield
-4.76%
-0.74%
1-Year Price Total Return
-21.2%
-29.11%
Beta (5-Year)
1.315
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$7.65
200-day SMA
Sell
Level
$7.27
Bollinger Bands (100)
Sell
Level
7.06 - 8.48
Chaikin Money Flow
Sell
Level
-3.4M
20-day SMA
Sell
Level
$8.10
Relative Strength Index (RSI14)
Sell
Level
35.45
ADX Line
Sell
Level
13.78
Williams %R
Buy
Level
-83.7963
50-day SMA
Sell
Level
$8.09
MACD (12, 26)
Sell
Level
-0.22
25-day Aroon Oscillator
Sell
Level
-56
On Balance Volume
Neutral
Level
8.8M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-0.8389)
Sell
CA Score
(Annual)
Level (-0.7861)
Buy
Beneish M-Score
(Annual)
Level (-2.7838)
Buy
Momentum Score
Level (6)
Sell
Ohlson Score
Level (0.9596)
Buy
Piotroski F Score
(Annual)
Level (4)
Sell
Quality Ratio Score
Level (3)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Health Catalyst Inc provides data and analytics technology and services to healthcare organizations. It has two operating segments. The Technology segment, the key revenue driver, includes data platforms, analytics applications, and support services. This generates revenues mainly from contracts that are cloud-based subscription arrangements, time-based license arrangements, and maintenance and support fees; the Professional Services segment is generally the combination of analytics, implementation, strategic advisory, outsourcing, and improvement services to deliver expertise to its customers to more fully configure and utilize the benefits of the technology offerings.
Stock Forecast FAQ
In the current month, HCAT has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The HCAT average analyst price target in the past 3 months is --.
-
Where Will Health Catalyst Stock Be In 1 Year?
According to analysts, the consensus estimate is that Health Catalyst share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Health Catalyst?
Analysts are divided on their view about Health Catalyst share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Health Catalyst is a Sell and believe this share price will drop from its current level to --.
-
What Is Health Catalyst's Price Target?
The price target for Health Catalyst over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is HCAT A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Health Catalyst is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of HCAT?
You can purchase shares of Health Catalyst via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Health Catalyst shares.
-
What Is The Health Catalyst Share Price Today?
Health Catalyst was last trading at $6.98 per share. This represents the most recent stock quote for Health Catalyst. Yesterday, Health Catalyst closed at $7.10 per share.
-
How To Buy Health Catalyst Stock Online?
In order to purchase Health Catalyst stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 23
Quantum [QMCO] is down 0.24% over the past day.
Sell
46
NUKK alert for Dec 23
Nukkleus [NUKK] is up 5% over the past day.
Sell
1
IIPR alert for Dec 23
Innovative Industrial Properties [IIPR] is down 5.65% over the past day.
